Allen, R.P., McCann, U.D., Ricaurte, G.A. (1993) Persistent effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. Sleep, 16, 560-4

Baggott, M., Jerome, L., Stuart, R. (2001) A Review of the English-Language Scientific and Medical Literature.

Broening, H.W., Bowyer, J.F., Slikker, W. (2001) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) Coorelates With the Magnitude of MDMA Induced Thermal Response. J Pharmacol Exp Ther 275,

Carlson, N.R. (2001) Physiology of Behavior. Massachusetts: Allyn and Bacon.

Convertino, V.A., Armstrong, L.E., Coyle, E.F., Mack, G.W., Sawka, M.N., Senay, L.C. Jr., Sherman, W.M. (1996)American College of Sports Medicine position stand. Exercise and fluid replacement. Med Sci Sports Exerc 28, i-vii

Cooper, J.R., Bloom, F.E., Roth, R.H. (1982) The Biochemical Basis of Neuropharmacology New York/Oxford: Oxford University Press.

Downing, J. (1986) The psychological and physiological effects of MDMA on normal volunteers. Journal of Psychoactive Drugs. 18,(4):335-40

Fineschi, V., Masti, A. (1996) Fatal poisoning by MDMA (ecstasy) and MDEA: a case report. Int J Legal Med 108, 272-275,

Frederick, D.L., Paule, M.G. (1997) Effects of MDMA on complex brain function in laboratory animals. Neuroscience and Behavioral Reviews 21, 67-78,

Gamma, A., Buck, A., Berthold, T., Vollenweider, F. (2001) No difference in brain activation during cognitive performance between Ecstasy (MDMA) users and controls: a [H2(15)O]-PET study. J Clinical Psychopharmacology, 21K(1), 66-71,

Gijsman, H.J., Verkes, R.J. van Gerven, A., Cohen, A. (1999) MDMA study. Neuropsychopharmacology 296, 207-15,

Granoff, M.I., Ashby, C.R. Jr. (1998) The Effect of the Repeated Administration of the Compound 3,4-methylenedioxymethamphetamine on the Response of Rats to the 5-HT2 receptor agonist +- -1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane Neuropshycobioloby 37, 36-40,

Green, A.R., Cross, A.J., Goodwin, G.M. (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). PSychopharmacology 119, 247-260,

Greer, G., Tolbert, R. (1986) Subjective reports of the effects of MDMA in a clinical setting J Psychoactive Drugs, 18(4), 319-27

Greer, G., Tolbert, R. (1998) A method of conducting therapeutic sessions with MDMA J Psychoactive Drugs, 30(4), 371-9

Grinspoon, L., Bakalar, J.B., (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40,(3):393-404,

Grob, C.S., Poland, R.E., Chang, L., Ernst, T. (1996) Pyschobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73, 103-7,

Gudelsky, G.A., Yamamoto, B.K., Nash, F. (1994) Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonsists. J Pharmacol Exp Ther 264, 225-230,

Heffernan, T. M., Jarvis, H., Rodgers, J., Scholey, A. B., & Ling, J. (2001). Prospective memory, everyday cognitive failure and central executive function in recreational users of ecstasy. Human Psychopharmacology: Clinical & Experimental, 16(8), 607-612.

Henry, J.A., Jeffreys, K.J., Dawling, S. (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet, 340, 384-387,

Henry, J.A., Hill, I.R. (1998) Fatal interaction between ritonavir and MDMA. Lancet, 352, 1751-2,

Jansen, K.L.R. (1997) Adverse psychological effects associated with the use of Ecstasy (MDMA) and their treatment. In: Ecstasy Reconsidered (Saunders, N. ed.) pp112-128. Nicholas Saunders, 14 Neal's Yard, London WC2 9DP, United Kingdom.

Johnson, E.A., Shvedova, A.A., Kisin, E., O'Callaghan, J.P., Kommineni, C., Miller, D.B. (2002) d-MDMA during vitamin E deficiency: effects on dopaminergic neurotoxicity and hepatotoxicity. Brain Res 933(2): 150-163.

Joseph, R. (1993) The Naked Neuron: Evolution and the Languages of the Body and Brain New York: Plenum Press.

Kemmerling, K., Haller, R. & Hinterhuber, H. (1996) das neuropsychiatrische Risiko von 3,4 methylenedioxy-methamphetamine (Ecsatsy). Neuropsychiatrie 10, 94 p; 102.

Kirsh, M. M. (1986) Designer Drugs Minneapolis: CompCare Publications.

Leonard, B. E. (1997) Fundamentals of Psychopharmacology New York: John Wiley and Sons.

LeSage, M., Clark, R., & Poling, A. (1993). MDMA and memory: The acute and chronic effects of MDMA in pigeons performing under a delayed-matching-to-sample procedure. Psychopharmacology, 110(3), 327-332.

Mas, M., Farre, M., de la Torre, R., Roset, P.N., Ortuno, J., Segura, J., Cami, J. (1999) Cardiovascular and neuroendocrine effects and pharmokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290, 136-45,

McCann, U.D., Szabo, Z., Scheffel, U., Dannais, R., Ricaurte, G. (1998) Positron emission tomographic evidence of toxic effect of MDMA ('Ecstasy') on brain serotonin neurons in human beings. Early Report,

McCann, U.D., Eligulashvili, V., Ricaurte, G.A. (2000) (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42, 11-6,

Ricaurte, G.A., McCann, U.D. (2001) Assessing long-term effects of MDMA (Ecstasy). Lancet 368, 1864,

Mechan, A., Moran, P.M., Elliott, J.M., Young, A., Joseph, M., Green, R. (2002) A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on the subsequent long-term behavior of rats in the plus maze and the open field. J Pharmacol Exp Ther 159, 167-175,

Milosevic, A., Agrawal, N., Redfearn, P., Mair, L. (1999) The occurrence of toothwear in users of Ecstasy Community Dent Oral Epidemiol Vol 27 (No 4), 283-287

Molliver, M. E., Mamounas, L.A., and Wilson, M.A. (1989) Effects of neurotoxic amphetamines on serotonergic neurons: immunocytochemical studies In: Pharmacology and Toxicology of Amphetamine and Related Designer Drugs, ED.s K. Asghar, E De souza, NIDA Research Monograph 94, Maryland, . pp270-304

Nichols, D.E. (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18, 305-13, Niesink, R.J.M., Jaspers R.M.A., Kornet, L.M.W., van Ree, J.M. (1999) Drugs of Abuse and Addiction: Neurobehavioral Toxicology New York: CRC Press.

O'Shea, E., Granados, R., Esteban, B., Colado, M.I., Gree, R. (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of anministration of MDMA (ecstasy). Neuropharmacology Ther 27, 919-927,

Pacifici, R., Zuccaro, P., Farre, M., Pichini, S., Di Carlo, S., Roset, P.N., Hernandez, L.C., Ortuno, J., Segura, J., Cami, J., de la Torre, R. (2000) Immunomodulating activity of MDMA. Ann N Y Acad Sci 914, 215-24,

Pacifici, R., Zuccaro, P., Farre, M., Pichini, S., Di Carlo, S., Roset, P.N., Ortuno, J., Segura, J., de la Torre, R. (1999) Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci 65, L309-16,

Pacifici, R., Zuccaro, P., Lopez, C.H., Pichini, S., Di Carlo, S., Farre, M., Roset, P.N., Ortuno, J., Segura, J., Torre, R.L. (2001) Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296, 207-15,

Perrine, D.M. (1996) The Chemistry of Mind-altering Drugs: History, Pharmacology and Cultural Context Washington, DC: American Chemical Society.

Reneman, L., Majoie, C. B., Habraken, J. B., & den Heeten, G. J. (2001). Effects of ecstasy (MDMA) on the brain in abstinent users: Initial observations with diffusion and perfusion MR imaging. Radiology, 220(3), 611-617.

Semple, D.M., Ebmeier, K.P., Glabus, M.F., O'Carroll, R.E., Johnstone, E.C. (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry, 1999; 175, 63-9

Schmidt, C.J., Kehne, J.H. (1990) Neurotoxicity of MDMA: neurochemical effects. Ann N Y Acadademy Scientific Therapy 600,

Schmidt, C.J., Taylor, V.L., Abbate, G., Riedezak, T. (1991) 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of Dopamine synthesis: Reversal by L-Dopa. J Pharmacol Exp Ther 256, 230-236,

Simeon, D. (2004). Depersonalisation disorder: A contemporary overview. CNS Drugs, 18(6), 343-354.

Williams, H., Meager, D., & Galligan, P. (1993) MDMA (Ecstasy). A case of possible drug induced psychosis. Ir. J. Psychol. Med. 162, 43 p; 44.

Woodrow, G., Harnden, P., Turney, J.H. (1995) Acute renal failure due to accelerated hypertension following ingestion of 3,4-methylenedioxymethamphetamine ('ecstasy'). Nephrol Dial Translant 10, 399-400,

All original Calvin & Hobbes images are Bill Watterson & Universal Press Syndicate




Main Table of Contents